FDA Approves Enzalutamide for Nonmetastatic CRPC

July 13, 2018 – The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Pfizer and Astellas, the codevelopers of the antiandrogen agent. The approval is based on the phase III PROSPER trial, in which the combination of enzalutamide and androgen deprivation therapy (ADT) reduced the risk of metastases or death by 71% compared with ADT alone for patients with nonmetastatic … (leggi tutto)